Reference-batch COA YGIF26072101 · Clear purity vs assay reporting · Chiral identity review · Supplier qualification pathway
01. B2B S-Equol Supply & Technical Qualification
AIHerba® supports technical evaluation and international B2B sourcing of (S)-Equol at a stated ≥99% HPLC purity specification. This page focuses on identity, lot-specific analytical evidence, production documentation and qualification requirements rather than consumer treatment claims.
The documented reference lot is YGIF26072101 (manufactured 21 July 2026; 30.2 kg batch quantity in its COA). Current saleable lot, inventory quantity, shipment date and current batch test results must be confirmed individually. AIHerba supplies through a manufacturing/sourcing arrangement; manufacturing site attribution and authorizations are documented separately.
02. What Is (S)-Equol? Chemical Identity
S-Equol is the (S) enantiomer of equol, a metabolite that can arise from microbial conversion of the soy isoflavone daidzein. It is a defined molecule, not equivalent to a generic soybean extract or a soy-isoflavone mixture.
| Identity field | Value |
|---|---|
| Name | (S)-(−)-Equol / S-Equol |
| CAS | 531-95-3 |
| Molecular formula | C15H14O3 |
| Molecular weight | 242.27 g/mol |
| Chemical category | Chiral isoflavone metabolite |
For distinctions between equol, S-Equol, R-Equol and soybean starting materials, consult the Equol identity guide.
03. S-Equol vs. R-Equol and Racemic Equol
S-Equol and R-Equol share a molecular formula but differ in stereochemistry. Racemic equol contains both enantiomers. A high result from a conventional, non-chiral HPLC purity assay cannot, on its own, establish S-enantiomeric purity.
| Term | Supplier qualification question |
|---|---|
| S-Equol | Is the S configuration established with validated identity evidence? |
| R-Equol | Has the alternative enantiomer been assessed? |
| Racemic Equol | Is the S:R ratio known and declared? |
| Conventional HPLC purity | Does the method resolve both enantiomers? |
| Chiral HPLC | Are standards, peak assignment and method suitability documented? |
04. Product Specification & Available Grade
The supplied company specification identifies S-Equol as a white powder with purity ≥99% by HPLC. The 2026 reference COA contains an HPLC purity specification of ≥99% and a separate dry-basis assay acceptance range of 98.0–102.0%.
| Specification item | Current documented specification | Evidence |
|---|---|---|
| HPLC purity | ≥99% | 2026 reference COA |
| Assay on dried basis | 98.0–102.0% | 2026 reference COA |
| Appearance | White crystalline powder | 2026 reference COA |
| Loss on drying | ≤1.0% | 2026 reference COA |
| Ethanol residual solvent | <200 ppm | 2026 reference COA |
| Particle size | 95% passes 60 mesh (2026 COA); older specification lists 100% passes 100 mesh | Conflict: latest signed grade-specific TDS required |
Unverified 90%, water-dispersible and oil-dispersible grades are not represented here as current commercial offerings. Grade options require their own specifications and testing.
05. Reference Lot YGIF26072101 — COA Results
The following values reproduce the reported reference COA and must not be presented as guaranteed results for future orders.
| Analyte / property | Specification | Reference result |
|---|---|---|
| HPLC purity | ≥99% | 100.0% (as reported) |
| HPLC assay, dry basis | 98.0–102.0% | 99.82% |
| Melting point | 189–190°C | 189°C |
| Specific rotation [α]D25 | Report actual value | −23.53° |
| Loss on drying | ≤1.0% | 0.15% |
| Ethanol residual solvent | <200 ppm | 197 ppm |
| Mesh size | 95% passing 60 mesh | Conforms |
06. HPLC Purity, Assay & Method Interpretation
The same COA reports HPLC purity 100.0% and dry-basis assay 99.82%. These are different measurements and should not be merged into a single marketing number. The report does not include a full batch-matched chromatogram, system suitability, integration report or calibration details.
An older Equol-3 HPLC report dated 26 November 2024 is available for historical method context only. Its result must not be used as a chromatographic record or purity confirmation for reference lot YGIF26072101.
07. Chiral Identity & Enantiomeric Purity
For an ingredient sold specifically as S-Equol, stereochemical identity is a primary qualification requirement. A buyer may request a validated chiral HPLC or comparable orthogonal method that resolves the S and R forms, with appropriate standards and peak identification.
- Batch identifier and instrument/method version
- Reference standards and retention/assignment evidence
- S:R or enantiomeric purity result and reporting limit
- Raw chromatogram, integration output and quality approval
Specific rotation supports identity when measurement conditions and method suitability are defined; it should not be treated alone as a quantitative percentage of the S enantiomer.
08. Physical Properties, Mesh & Powder Handling
The reference COA records a white crystalline powder, a measured melting point of 189°C and a conforming sieve result against 95% passing 60 mesh. An older company specification gives 100% passing 100 mesh, so these figures require grade/version reconciliation before a particle-size marketing promise is made.
If a micronized grade is needed, request sieve data or D10/D50/D90 laser-diffraction results for the offered lot. Flow, electrostatic behavior, compressibility and powder dust considerations should be validated in the customer’s process.
09. Feedstock Traceability: Daidzein and Fermentation
The upstream EquoPro™ supplier presentation describes production from daidzein by microbial fermentation and subsequent isolation/purification. This is a route description from a supplier document, not an independent site audit or proof that the reference lot used a particular strain or feedstock source.
Quality teams should request the manufacturing site, source of daidzein, strain and processing aid declarations where applicable, and chain-of-custody records. Related technical reading: S-Equol source and production guide.
10. Manufacturing Process & Purification Control
Typical evaluation checkpoints for an S-Equol biotransformation process include feedstock approval, controlled bioconversion, downstream separation, purification, crystallization and final release testing. Actual flowchart, critical control points and yield claims should be aligned to the identified producing facility.
- Identity of actual legal manufacturer and manufacturing address
- Batch traceability from incoming precursor to finished lot
- Approved processing aids and any potential residual impurities
- Contamination control, change control and reprocessing policy
Do not interpret the upstream supplier’s presentation of a patented production flow as evidence that AIHerba owns the process or the underlying intellectual property.
11. Quality Systems & Manufacturing-Site Qualification
The upstream presentation lists NSF, FSSC 22000, HACCP, ISO 22000, Halal, Kosher and other certifications. These are supplier claims and cannot be transferred to AIHerba as if issued to the same legal entity.
Buyers should request certificates showing exact company name, site address, accreditation or registration number, expiration date and product/process scope. AIHerba can coordinate collection of authorized supplier documentation as needed.
12. Residual Solvents, Metals & Microbiology
The reference batch COA provides residual ethanol <200 ppm specification with a result of 197 ppm. Elemental impurities including Pb, As, Cd and Hg are listed as “Conforms” against stated limits, rather than numerical measured values. Microbiological release tests are also reported as conforming.
| Control | Reference COA | Qualification follow-up |
|---|---|---|
| Ethanol | 197 ppm (<200 ppm) | Full solvent panel and method / quantitation limit |
| Pb, As, Cd, Hg | Conforms | Quantitative ICP-MS results and detection limits |
| Total aerobic count | Conforms (≤1,000 CFU/g) | Actual result for supply lot |
| Yeast and mold | Conforms (≤100 CFU/g) | Actual result for supply lot |
| E. coli, Salmonella, S. aureus | Not detected | Batch method, sampling plan and certificate |
USP test-procedure references do not, by themselves, prove compliance with every target market or finished-product use.
13. Carrier, Allergen & Composition Disclosure
The reference COA identifies S-Equol powder but does not provide an independent complete composition declaration identifying all carriers, excipients, processing aids or remaining soy-derived material. Consequently, “carrier-free,” “soy-free,” “organic,” and “non-GMO” require their own substantiation.
For sensitive formulations, the customer should obtain appropriate soy allergen, GMO and processing-aid statements issued by the actual manufacturer, where relevant.
14. Solubility & Formulation Compatibility
S-Equol is being evaluated in capsule, tablet, powdered nutrition and other specialty formulations. The supplied documents do not establish instant cold-water solubility, validated oil dispersibility or performance across specific pH, concentration and processing conditions.
- Specify target concentration, solvent system and pH
- Assess dissolution, uniformity and physical stability under use conditions
- Validate compatibility with excipients, packaging and heat exposure
- Use a grade-specific TDS rather than inferring performance from generic equol literature
Customer formula feasibility, finished-product stability and suitability are determined by application testing and destination-market requirements.
15. Storage, Shelf Life & Packaging
The 2026 reference COA states storage in a tight, light-resistant container, at controlled room temperature in a dry place, with a 36-month stated shelf life under proper conditions. The listed packaging uses an inner sterile bag and an outer aluminum-foil bag.
The COA expiry date is 20 July 2029. A full stability protocol and test data should be obtained before applying the same shelf-life claim across all grades and packages. The commercial pack weight, retest policy and dispatch lead time remain subject to confirmation.
16. Research & Product Development Context
Scientific literature has studied S-Equol and its interaction with estrogen-related signaling and biological processes. These studies motivate commercial R&D interest but should not be converted into unqualified treatment, menopause relief, cancer prevention or hormone-balancing claims for the offered ingredient.
For study summaries and their limitations, see the S-Equol clinical evidence and safety guide. Application-specific claims depend on validated finished-product data and applicable labeling rules.
17. U.S., EU & International Regulatory Qualification
Regulatory status must be evaluated for the precise material identity, production route, intended use, target population and destination country. A CAS entry, laboratory purity value or GMP certificate does not confer food, supplement, cosmetic or drug approval.
The FDA issued final recommendations on NDI identity and safety information on 19 October 2026. They describe notification documentation expectations, not approval of this S-Equol grade. EU authorization questions should be reviewed against the Novel Food Catalogue and the Union list and with local regulatory specialists.
18. Sampling, MOQ, Quotation & Commercial Supply
Qualification can begin with a document review and a requested analytical or formulation sample, subject to actual lot availability and sample permissions. MOQ, unit prices, country-specific import conditions, Incoterms, production lead time, packaging unit and delivery schedule require a written quotation.
| Buyer input | Why it matters |
|---|---|
| Grade and assay method | Ensures the same material is being quoted |
| Required quantity and annual forecast | Defines pilot or commercial tier |
| Destination country and intended use | Regulatory and logistics screening |
| Required documentation | Speeds QA qualification |
| Requested delivery terms | Avoids assumptions about customs/taxes |
For purchasing process guidance visit the S-Equol supplier qualification and bulk sourcing guide.
19. Supplier Qualification FAQ
What does ≥99% HPLC purity mean?
It is the stated chemical purity specification by the approved HPLC method; it is not proof of absolute purity or the S:R enantiomeric ratio.
Is the 2026 COA the current shipping batch?
Not confirmed. YGIF26072101 is the documented reference lot; request a current supply-lot COA.
Can the 2024 HPLC file support the 2026 lot?
No. It is an older Equol-3 sample with different testing and no established lot match.
Is a chiral HPLC report available?
A batch-linked report has not yet been supplied for independent verification; request confirmation.
Is the particle size 60 or 100 mesh?
The 2026 reference COA uses 95% pass 60 mesh; the older specification lists 100% pass 100 mesh. Confirm the offered grade and updated TDS.
Can the product be used in supplements worldwide?
No global approval is implied. The intended use and manufacturing identity require market-by-market regulatory review.
What is the documented packaging?
The reference COA states sterile inner bag and aluminum-foil outer bag; current commercial packaging weight requires confirmation.
20. References & Technical Disclaimer
- FDA GSRS substance identity: S-Equol (CAS 531-95-3)
- U.S. FDA (2026), NDI identity and safety guidance
- European Commission Novel Food status catalogue
- European Commission Union list of novel foods
- Company reference COA: YGIF26072101, manufactured 21 July 2026 (not an assertion of current stock)
- Historical HPLC: Equol-3, 26 November 2024 (not batch-matched)
Disclaimer: This page presents industrial ingredient technical qualification information. Reference results are not a guarantee of results for another batch. No therapeutic efficacy, regulatory clearance, organic origin, site certification or unverified manufacturing claim is implied.
Send your target market, quantity, analytical requirements and project timeline. Email: sales@aiherba.com · WhatsApp: +86 199 2901 8987.





